AB041. Partial versus complete thymectomy for t1a (<5 cm) thymoma: a propensity-matched analysis of oncologic and long-term immune-associated outcomes
Year: 2026
Type: conference-abstract
Abstract: BACKGROUND: Accumulating evidence suggests that adult thymic preservation may have long-term oncologic and immunologic implications. Thymectomy has been associated with increased cancer and mortality, and intact thymic function linked to T-cell diversity and cancer immunotherapy response. Whether complete thymectomy is necessary for small, localized thymomas remains unknown. At two NCI-designated cancer centers, we compared oncologic, perioperative, and exploratory long-term immune-associated outcomes after partial (PT) versus complete thymectomy (CT). METHODS: We retrospectively identified 169 patients who underwent PT (n=32) or CT (n=137) for pT1a thymoma <5 cm from 2005–2025. Optimal full propensity-score matching yielded 29 PT and 131 CT patients matched on age, sex, race, smoking, prior cardiothoracic surgery, pulmonary and renal comorbidity, preoperative myasthenia gravis and autoimmune disease, prior malignancy, WHO histology, capsular invasion, and mediastinal pleural invasion. Recurrence was analyzed with death as a competing event. Long-term outcomes were retrospectively abstracted from institutional records and included new malignancy or autoimmune disease within five years and infection requiring hospitalization within ten years. RESULTS: Median follow-up was 5.1 years. R0 resection was achieved in all PT patients. No recurrences occurred after PT; recurrence did not differ between groups (P=0.55). There was no difference in OS (P=0.19, 5yOS: 100% PT, 94.7% CT). PT reduced median operative time by 43 minutes (97 vs. 140 minutes; P=0.001), while complication rates were similar (17.2% vs. 23.7%; P=0.47). One recurrent laryngeal and one phrenic nerve injury occurred after CT, both requiring operative repair; neither occurred after PT. New malignancy occurred in 13.8% vs. 13.7% (P=0.99), new autoimmune disease in 0% vs. 8.4% (P=0.22), infection requiring hospitalization in 6.9% vs. 10.7% (P=0.74), and new myasthenia gravis in 0% vs. 2.3% (P>0.99). Composite immune-associated morbidity was 20.7% vs. 27.5% (P=0.47). CONCLUSIONS: Among selected patients with resected T1a thymoma <5 cm, PT was associated with shorter operative time and no observed recurrence, without significant differences in perioperative, oncologic, or long-term immune-associated outcomes. Limited sample size, low event rates, follow-up duration, and retrospective outcome ascertainment preclude conclusions regarding oncologic equivalence or immunologic benefit. These findings support prospective evaluation of thymus-preserving surgery with standardized surveillance and measures of thymic function.
Source: Mediastinum
Language: English
Subfield: Clinical Neurology
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
OpenAlex ID: W7225118191
